Skip to main content
. 2021 Oct 29;8:1299–1309. doi: 10.2147/JHC.S334933

Table 3.

Prognostic Factors on Overall Survival by Cox Proportional-Hazards Model

UVA MVA in NLR Model MVA in PLR Model
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age >65 years 0.79 (0.50–1.24) 0.304
Female vs male 1.47 (0.87–2.48) 0.151
Underlying liver disease
 HBV vs no 0.79 (0.50–1.25) 0.309
 HCV vs no 1.00 (0.62–1.62) 0.987
CTP class B vs A 2.07 (1.28–3.33) 0.003 2.35 (1.27–4.37) 0.007 2.48 (1.38–4.44) 0.002
Total GTV (per 10 cc increase) 1.002 (0.996–1.008) 0.566
Multiple tumors 1.81 (1.09–3.03) 0.023 1.99 (1.08–3.68) 0.028 1.71 (0.93–3.15) 0.083
Macrovascular invasion 2.20 (1.36–3.55) 0.001 1.51 (0.87–2.62) 0.143 1.92 (1.13–3.26) 0.016
Extrahepatic spread 3.35 (1.92–5.85) <0.001 1.68 (0.91–3.08) 0.097 1.61 (0.85–3.04) 0.141
Performance status ≥2 2.01 (1.17–3.46) 0.012 0.77 (0.40–1.50) 0.443 1.14 (0.61–2.15) 0.676
AFP level ≥400 ng/mL 1.67 (1.06–2.65) 0.029 1.72 (1.00–2.95) 0.051 1.59 (0.94–2.69) 0.081
BED ≥85.5 Gy 1.16 (0.73–1.83) 0.527
Prior treatment no.
 0 Reference 0.552
 1–3 1.30 (0.78–2.16) 0.311
 >3 1.29 (0.68–2.46) 0.431
Pre-RT Hgb (per 1 g/dL increase) 0.91 (0.82–1.00) 0.057 0.97 (0.87–1.09) 0.629 1.01 (0.91–1.13) 0.860
ASL 2.33 (1.44–3.76) 0.001 1.01 (0.54–1.90) 0.971 1.67 (0.99–2.84) 0.056
Pre-RT NLR (per 1-unit increase) 1.20 (1.10–1.30) <0.001 1.24 (1.12–1.38) <0.001
Delta-NLR (per 1-unit increase) 1.11 (1.05–1.18) 0.001 1.10 (1.02–1.18) 0.011
Pre-RT PLR (per 10-unit increase) 1.02 (1.00–1.05) 0.070 1.00 (0.97–1.04) 0.813
Delta-PLR (per 10-unit increase) 1.01 (0.99–1.02) 0.401

Abbreviations: AFP, α-fetoprotein; ASL, acute severe lymphopenia; BED, biologically effective dose; CI, confidence interval; CTP, Child–Turcotte–Pugh liver function scale; GTV, gross tumor volume; HBV, hepatitis B virus; HCV, hepatitis C virus; Hgb, hemoglobin; HR, hazard ratio; MVA, multivariable analysis; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; RT, radiotherapy; UVA, univariable analysis.